Safety and immunogenicity of a monovalent MF59^庐-adjuvanted A/H1N1 vaccine in HIV-infected children and young adults

详细信息	查看全文 | 推荐本文 |

• 作者：Paolo Palma^a ; ^{paolo.palma@opbg.net} ; Maria Luisa Romiti^b ; Stefania Bernardi^a ; Giuseppe Pontrelli^a ; Nadia Mora^b ; Veronica Santilli^b ; Hyppolite Kuekou Tchidjou^b ; Angela Aquilani^b ; Nicola Cotugno^b ; Federico Alghisi^c ; Vincenzina Lucidi^c ; Paolo Rossi^a ; Iyadh Douagi^d
• 关键词：Pandemic influenza ; H1N1 ; HIV ; Pediatric ; MF59
• 刊名：Biologicals
• 出版年：2012
• 期刊代码：162_10451056
• 类别：bio
• 出版时间：March, 2012
• 卷：40
• 期：2
• 页码：134-139
• 文件大小：374 K

摘要

Background

This Phase IV study evaluated the safety and immunogenicity of a two-dose, MF59^庐-adjuvanted (Novartis Vaccines, Marburg, Germany), monovalent, A/H1N1 pandemic influenza vaccination schedule in Human Immunodeficiency Virus (HIV) positive children and young adults.

Methods

A total of 83 children infected with HIV-1, and 37 non-immunocompromised, age-matched controls were enrolled. All participants received two vaccine doses administered three weeks apart. Antibody responses were assessed by haemagglutination assay at baseline, three weeks after each vaccine dose, and six months after immunization. Vaccines were evaluated according to European influenza vaccine licensure criteria.

Results

The investigational vaccine was well tolerated. After the first vaccine dose, seroconversion rates were significantly lower in HIV-positive patients (60%) than controls (82%), with GMTs of 419 and 600, respectively. No significant differences in seroconversion rates were observed between the two study groups in response to the second vaccine dose. Persisting antibody titers were similar for both HIV-positive and non-infected controls, six months after immunization.

Conclusion

One dose of MF59-adjuvanted vaccine was sufficient to provide adequate levels of seroprotection against A/H1N1 influenza disease in HIV-positive children. However, a two-dose vaccination schedule may be optimal for this population.